Literature DB >> 7523435

Optimizing the effectiveness of hematopoietic growth factors.

D E Williams1.   

Abstract

Hematopoiesis is regulated in a very precise fashion by a balance between both positive and negative growth factor signals in the hematopoietic microenvironment. Many of these growth factor signals have been identified and are available as recombinant proteins. At the present time, the approved uses for hematopoietic growth factors involve their use to facilitate blood cell production in situations of hematopoietic suppression or in cases where endogenous growth factor production is inappropriately low. Recent studies with the hematopoietic growth factors are looking at innovative strategies for their use and new clinical situations in which to evaluate their effectiveness. This review looks at some of these new uses for hematopoietic growth factors.

Mesh:

Substances:

Year:  1994        PMID: 7523435     DOI: 10.1007/bf01552307

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  48 in total

1.  Mobilization of hematopoietic stem cells (CFU-C) into the peripheral blood of man by endotoxin.

Authors:  M J Cline; D W Golde
Journal:  Exp Hematol       Date:  1977-05       Impact factor: 3.084

2.  The growth of mouse bone marrow cells in vitro.

Authors:  T R Bradley; D Metcalf
Journal:  Aust J Exp Biol Med Sci       Date:  1966-06

Review 3.  Hematopoietic regulators: redundancy or subtlety?

Authors:  D Metcalf
Journal:  Blood       Date:  1993-12-15       Impact factor: 22.113

4.  Abrogating chemotherapy-induced myelosuppression by recombinant granulocyte-macrophage colony-stimulating factor in patients with sarcoma: protection at the progenitor cell level.

Authors:  S Vadhan-Raj; H E Broxmeyer; W N Hittelman; N E Papadopoulos; S P Chawla; C Fenoglio; S Cooper; E S Buescher; R W Frenck; A Holian
Journal:  J Clin Oncol       Date:  1992-08       Impact factor: 44.544

5.  Collection of peripheral blood stem cells in multiple myeloma following single high-dose cyclophosphamide with and without recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF).

Authors:  J M Boiron; G Marit; C Fabéres; P Cony-Makhoul; C Foures; A M Ferrer; G Cristol; A Sarrat; D Girault; J Reiffers
Journal:  Bone Marrow Transplant       Date:  1993-07       Impact factor: 5.483

6.  Comparison of three remission induction regimens and two postinduction strategies for the treatment of acute nonlymphocytic leukemia: a cancer and leukemia group B study.

Authors:  H Preisler; R B Davis; J Kirshner; E Dupre; F Richards; H C Hoagland; S Kopel; R N Levy; R Carey; P Schulman
Journal:  Blood       Date:  1987-05       Impact factor: 22.113

Review 7.  Physiologic and molecular biology of erythropoietin.

Authors:  A J Erslev; J Caro
Journal:  Med Oncol Tumor Pharmacother       Date:  1986

8.  Recombinant human erythropoietin in the treatment of anemia associated with human immunodeficiency virus (HIV) infection and zidovudine therapy. Overview of four clinical trials.

Authors:  D H Henry; G N Beall; C A Benson; J Carey; L A Cone; L J Eron; M Fiala; M A Fischl; S J Gabin; M S Gottlieb
Journal:  Ann Intern Med       Date:  1992-11-01       Impact factor: 25.391

9.  Granulocyte-macrophage colony-stimulating factor enhances the cytotoxic effects of cytosine arabinoside in acute myeloblastic leukemia and in the myeloid blast crisis phase of chronic myeloid leukemia.

Authors:  S A Cannistra; P Groshek; J D Griffin
Journal:  Leukemia       Date:  1989-05       Impact factor: 11.528

10.  Long-term erythropoiesis from constant numbers of CD34+ cells in serum-free cultures initiated with highly purified progenitor cells from human bone marrow.

Authors:  P M Lansdorp; W Dragowska
Journal:  J Exp Med       Date:  1992-06-01       Impact factor: 14.307

View more
  1 in total

Review 1.  Cytokine measurements and interpretation of cytokine assays in human disease.

Authors:  T L Whiteside
Journal:  J Clin Immunol       Date:  1994-11       Impact factor: 8.317

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.